Department of Molecular Medicine, School of Medical Science, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.
Department of Pathology, School of Medical Sciences Komfo Anokye Teaching Hospital, Kumasi, Ghana.
PLoS One. 2018 Aug 23;13(8):e0202790. doi: 10.1371/journal.pone.0202790. eCollection 2018.
Head and neck cancers include carcinomas of the oral cavity, larynx, sinonasal tract and nasopharynx. Studies on molecular expression of prognostic tumour markers in Ghana are scarce. The purpose of this study was to determine the expression of p53, p16, EGFR, Cyclin-D1 and HER2 among patients with non-oropharyngeal head and neck squamous cell carcinoma (HNSCC).
Tissue microarrays from 154 histologically confirmed non-oropharyngeal HNSCC at the Komfo Anokye Teaching Hospital from 2006-2014 were constructed using duplicate cores of representative and viable areas from tumours. Expression of EGFR, p53, p16, Cyclin-D1 and HER2 was evaluated using immunohistochemistry.
For non-oropharyngeal HNSCC, majority of the cases (66.2%; 102/154) had stage IV disease. EGFR was the most expressed molecular marker (29.4%; 25/85) followed by p53 (24.0%; 29/121), p16 (18.3%; 23/126) and Cyclin-D1 (10.0%; 12/120). HER2 was not expressed in any of the cases. There was a significantly (p = 0.022) higher expression of Cyclin-D1 in tumours of the oral cavity (19.6%; 9/46) than in those of the larynx (4.7%; 2/43) and nose (3.2%; 1/31). Tumours in stages I-III were more frequently positive for p16 (28.6%; 12/42) than tumours in stage IV (13.1%; 11/84).
Expression of p53, EGFR, p16 and Cyclin-D1 in non-oropharyngeal HNSCC in Ghana is largely similar to what has been reported in published studies from other countries.
头颈部癌症包括口腔癌、喉癌、鼻窦道和鼻咽癌。加纳关于预后肿瘤标志物分子表达的研究很少。本研究旨在确定非口咽头颈部鳞状细胞癌（HNSCC）患者中 p53、p16、EGFR、Cyclin-D1 和 HER2 的表达情况。
使用来自 2006 年至 2014 年科姆福·阿诺克耶教学医院的 154 例经组织学证实的非口咽 HNSCC 组织微阵列，从肿瘤的代表性和可存活区域构建重复核心。使用免疫组织化学评估 EGFR、p53、p16、Cyclin-D1 和 HER2 的表达。
对于非口咽 HNSCC，大多数病例（66.2%；102/154）为 IV 期疾病。最表达的分子标志物是 EGFR（29.4%；25/85），其次是 p53（24.0%；29/121）、p16（18.3%；23/126）和 Cyclin-D1（10.0%；12/120）。没有病例表达 HER2。口腔肿瘤（19.6%；9/46）中 Cyclin-D1 的表达明显高于喉肿瘤（4.7%；2/43）和鼻肿瘤（3.2%；1/31）（p = 0.022）。I-III 期肿瘤中 p16 的阳性表达率（28.6%；12/42）高于 IV 期肿瘤（13.1%；11/84）。
加纳非口咽 HNSCC 中 p53、EGFR、p16 和 Cyclin-D1 的表达与其他国家发表的研究报道基本相似。
